Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SOT109 |
| Synonyms | |
| Therapy Description |
SOT109 is an antibody-drug conjugate (ADC) comprising an antibody targeting CDH17 linked to exatecan, which potentially inhibits growth of CDH17-expressing tumors (Cancer Res (2025) 85 (8_Supplement_1): 5469). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SOT109 | SOT-109|SOT 109 | SOT109 is an antibody-drug conjugate (ADC) comprising an antibody targeting CDH17 linked to exatecan, which potentially inhibits growth of CDH17-expressing tumors (Cancer Res (2025) 85 (8_Supplement_1): 5469). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07693751 | Phase Ib/II | SOT109 | A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer | Not yet recruiting | USA | 1 |